Year Book of Dermatology - 2018
Psoriasis
Häftad, Engelska, 2019
729 kr
Tillfälligt slut
This book brings to you a collection of meticulously chosen articles focusing on the latest advances in management of Psoriasis from various peer reviewed journals that were published in the previous year. Each article has been reviewed by subject reviewers who have written comments on value of the article, previous knowledge on the subject, what the article adds to the prevailing knowledge and practices, strong points and weaknesses of the article, and other similar observations that have come in the last 12-month period.Each article is accompanied by key messages, summarizing the article as well as highlighting the clinical experience of the reviewers. Tjhis is a must read book for dermatologists, physicians, and postgraduate students.
Produktinformation
- Utgivningsdatum2019-02-28
- Mått171 x 241 x undefined mm
- Vikt310 g
- FormatHäftad
- SpråkEngelska
- Antal sidor178
- FörlagJaypee Brothers Medical Publishers
- ISBN9789352705931
Tillhör följande kategorier
- 1. Apremilast in Psoriasis–A Prospective Real-world Study 12. Comparative Effectiveness of Abatacept, Apremilast, Secukinumab and Ustekinumab Treatment of Psoriatic Arthritis: A Systematic Review and Network Meta-analysis3. Management of Common Side Effects of Apremilast4. Apremilast for the Treatment of Moderate?to?Severe Palmoplantar Psoriasis: Results from a Double?Blind, Placebo?Controlled, Randomized Study5. Long-term Safety and Tolerability of Apremilast in Patients with Psoriasis: Pooled Safety Analysis for ?156 Weeks from 2 Phase 3, Randomized Controlled Trials (ESTEEM 1 and 2)6. Secukinumab and Apremilast Combination Therapy for Recalcitrant Psoriasis7. Apremilast: A Review in Psoriasis and Psoriatic Arthritis8. Serum Squamous Cell Carcinoma Antigen in Psoriasis: A Potential Quantitative Biomarker for Disease Severity9. Long-term Real-life Safety Profile and Effectiveness of Fumaric Acid Esters in Psoriasis Patients: A Single-Centre, Retrospective, Observational Study10. Association between Circulating 25-hydroxyvitamin D Levels and Psoriasis, and Correlation with Disease Severity: A Meta-analysis11. Maintenance of Skin Clearance with Ixekizumab Treatment of Psoriasis: Three-Year Results from the UNCOVER-3 Study12. Psoriasis and the Risk of Diabetes: A Prospective Population-based Cohort Study13. Psoriatic Patients with Chronic Viral Hepatitis do not have an Increased Risk of Liver Cirrhosis Despite Long-term Methotrexate Use: Real-world Data from a Nationwide Cohort Study in Taiwan14. Reporting of Outcomes in Randomized Controlled Trials on Nail Psoriasis: A Systematic Review15. Risk of Cancer in Patients with Psoriasis on Biological Therapies: A Systematic Review16. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis17. Secukinumab Treatment of Moderate to Severe Plaque Psoriasis in Routine Clinical Care: Real-life Data of Prior and Concomitant Use of Psoriasis Treatments from the PROSPECT Study18. Serum Levels of Psoriasin (S100A7) and Koebnerisin (S100A15) as Potential Markers of Atherosclerosis in Patients with Psoriasis19. Simulating the Life Course of Psoriasis Patients: The Interplay between Therapy Intervention and Marital Status20. Smoking Paradox in the Development of Psoriatic Arthritis among Patients with Psoriasis: A Population-based Study21. Stricturing and Fistulizing Crohn's Disease is Associated with Anti-tumor Necrosis Factor-induced Psoriasis in Patients with Inflammatory Bowel Disease22. Studying the Effect of Systemic and Biological Drugs on Intima-Media Thickness in Patients Suffering from Moderate and Severe Psoriasis23. Systemic Immune Mechanisms in Atopic Dermatitis and Psoriasis with Implications for Treatment24. The Akkermansia-muciniphila is a gut Microbiota Signature in Psoriasis25. Topical Corticosteroid Concerns among Parents of Children with Psoriasis Versus Atopic Dermatitis: A French Multicentre Cross-sectional Study26. Fumaric Acid Esters in Combination with a 6-week Course of Narrowband Ultraviolet B Provides an Accelerated Response Compared with Fumaric Acid Esters Monotherapy in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized Prospective Clinical Study27. Association between Obesity and Pediatric Psoriasis28. Real-world Health Outcomes in Adults with Moderate-to-Severe Psoriasis in the United States: A Population Study Using Electronic Health Records to Examine Patient-perceived Treatment Effectiveness, Medication Use, and Healthcare Resource Utilization29. Dietary Recommendations for Adults with Psoriasis or Psoriatic Arthritis from the Medical Board of the National Psoriasis Foundation: A Systematic Review30. Turmeric Tonic as a Treatment in Scalp Psoriasis: A Randomized Placebo-control Clinical Trial31. Prevalence of Psoriatic Arthritis in Patients with Psoriasis: A Systematic Review and Meta-analysis of Observational and Clinical Studies32. A Multicenter, Prospective, Observational Study Examining the Impact of Risk Factors, Such as BMI and Waist Circumference, on Quality of Life Improvement and Clinical Response in Moderate-to-Severe Plaque-type Psoriasis Patients Treated with Infliximab in Routine Care Settings of Greece33. A Multidimensional Assessment of the Burden of Psoriasis: Results from a Multinational Dermatologist and Patient Survey34. A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic Arthritis35. Analysis of Anti-tumour Necrosis Factor-induced Skin Lesions Reveals Strong T Helper 1 Activation with some Distinct Immunological Characteristics36. Association between Circulating Prolactin Levels and Psoriasis and Its Correlation with Disease Severity: A Meta-analysis37. Burden of Chronic Urticaria Relative to Psoriasis in Five European Countries38. Biologics Combined with Conventional Systemic Agents or Phototherapy for the Treatment of Psoriasis: Real-life Data from PSONET Registries39. Carboxytherapy for Treatment of Localized Chronic Plaque Psoriasis: Clinical and Histopathologic Evaluation40. Comparison of Effectiveness and Safety of Excimer Lamp Vs Topical Calcipotriol-clobetasol Propionate Combination in the Treatment of Palmoplantar Psoriasis41. Comparison of Indirubin Concentrations in Indigo naturalis Ointment for Psoriasis Treatment: A Randomized, Double-blind, Dosage-controlled Trial42. Efficacy and Safety of Tofacitinib for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-analysis of Randomized Controlled Trials43. Efficacy and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: Results of the Randomized, Double-blind, Phase III NAVIGATE Trial44. Effect of Secukinumab on Quality of Life and Psoriasis-related Symptoms: A Comparative Analysis Versus Ustekinumab from the CLEAR 52-week Study45. Differential Effects of Secukinumab vs. Ustekinumab for Treatment of Psoriasis on Quality of Life, Work Productivity and Activity Impairment: A Structural Equation Modelling Analysis46. Glucose Transporter-1 (GLUT-1) Expression in Psoriasis: Correlation with Disease Severity47. Exposure to Biological Therapies during Conception and Pregnancy: A Systematic Review48. Higher Coronary Plaque Burden in Psoriatic Arthritis is Independent of Metabolic Syndrome and Associated with Underlying Disease Severity49. Increased Levels of Lipocalin 2 in Palmoplantar Pustular Psoriasis50. Ixekizumab Treatment for Psoriasis: Integrated Efficacy Analysis of Three Double-blinded, Controlled Studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)51. Long-term Clinical Efficacy and Safety of Secukinumab for Japanese Patients with Psoriasis: A Single-center Experience52. Matching-adjusted Indirect Comparison of Efficacy in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab vs. Secukinumab53. Metabolic Syndrome in Psoriatic Arthritis: The Interplay with Cutaneous Involvement. Evidences from Literature and a Recent Cross-sectional Study54. IL-17C: A Unique Epithelial Cytokine with Potential for Targeting across the Spectrum of Atopic Dermatitis and Psoriasis55. Patient-reported Symptoms and Signs of Moderate-to-Severe Psoriasis Treated with Guselkumab or Adalimumab: Results from the Randomized VOYAGE 1 trial56. Effects of Treatment for Psoriasis on Circulating Levels of Leptin, Adiponectin and Resistin: A Systematic Review and Meta-analysis57. Subcutaneous Methotrexate in Patients with Moderate-to-Severe Psoriasis: A Critical Appraisal58. Management of Psoriasis in Patients with Inflammatory Bowel Disease: From the Medical Board of the National Psoriasis Foundation59. Interleukin 17, Inflammation, and Cardiovascular Risk in Patients with Psoriasis60. Levels of miR?31 and its Target Genes in Dermal Mesenchymal Cells of Patients with Psoriasis61. Serum Elafin as a Potential Inflammatory Marker in Psoriasis62. Sex Hormones, Erectile Dysfunction, and Psoriasis; A Bad Friendship!63. Psoriasis and Suicidality: A Systematic Review and Meta-analysis64. Psoriasis and Vitiligo are Close Relatives65. Psoriasis Is Associated with Risk of Obstructive Sleep Apnea Independently from Metabolic Parameters and Other Comorbidities: A Large Hospital-based Case-control Study66. Psoriasis, Fracture Risk and Bone Mineral Density: The HUNT Study, Norway67. Rate of Serious Infection in Patients Who Are Prescribed Systemic Biologic or Nonbiologic Agents for Psoriasis: A Large, Single Center, Retrospective, Observational Cohort Study68. Review of Phase III Trial Data on IL-23 Inhibitors Tildrakizumab and Guselkumab for Psoriasis69. Risk for Hepatitis B and C Virus Reactivation in Patients with Psoriasis on Biologic Therapies: A Retrospective Cohort Study and Systematic Review of the Literature70. Risk of Developing Psoriasis in Patients with Schizophrenia: A Nationwide Retrospective Cohort Study71. Risk of Malignancy with Systemic Psoriasis Treatment in the Psoriasis Longitudinal Assessment Registry72. Risk of Suicidality in People with Psoriasis: A Systematic Review and Meta-analysis of Cohort Studies73. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis74. Severity of Psoriasis Differs between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients75. Silencing of Homeobox A5 Gene in the Stratum Corneum of Psoriasis76. Skin-infiltrating, Interleukin-22-producing T cells Differentiate Pediatric Psoriasis from Adult Psoriasis77. Spotlight on Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: Design, Development, and Use in Therapy78. Systematic Review and Meta-analysis of the Association between Psoriasis and Metabolic Syndrome79. Th17 Inhibitors in Active Psoriatic Arthritis: A Systematic Review and Meta-analysis of Randomized Controlled Clinical Trials80. The Acitretin and Methotrexate Combination Therapy for Psoriasis Vulgaris Achieves Higher Effectiveness and Less Liver Fibrosis81. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review82. The Metabolic Analysis of Psoriasis Identifies the Associated Metabolites while Providing Computational Models for the Monitoring of the Disease83. The Relationship between Duration of Psoriasis, Vascular Inflammation and Cardiovascular Events84. The Relevance of Serum Vitamin D in Psoriasis: A Review85. The Risk of Malignancy among Biologic-naïve Pediatric Psoriasis Patients: A Retrospective Cohort Study in a US Claims Database86. Risk of Venous Thromboembolism in Patients with Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis: A General Population-based Cohort Study87. A 2-Year Observational Study on Treatment Targets in Psoriatic Arthritis Patients Treated with TNF Inhibitors88. Anthralin Modulates the Expression Pattern of Cytokeratins and Antimicrobial Peptides by Psoriatic Keratinocytes89. Association of Psoriasis and Psoriatic Arthritis with Osteoporosis and Pathological Fractures90. Associations between Body Mass Index and Severity of Psoriasis91. Bariatric Surgery and the Incidence of Psoriasis and Psoriatic Arthritis in the Swedish Obese Subjects Study92. Atorvastatin as Adjunctive Therapy for Chronic Plaque Type Psoriasis versus Betamethasone Valerate Alone: A Randomized, Double-blind, Placebo-controlled Trial93. British Association of Dermatologists Guidelines for Biologic Therapy for Psoriasis 201794. Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-life Data95. Chemerin as a Marker of Subclinical Cardiac Involvement in Psoriatic Patients96. Clinical Efficacy and IL-17 Targeting Mechanism of Indigo naturalis as a Topical Agent in Moderate Psoriasis97. Comparative Evaluation of Efficacy and Safety of Calcipotriol versus Tacalcitol Ointment, Both in Combination with NBUVB Phototherapy in the Treatment of Stable Plaque Psoriasis98. Comparison of Ixekizumab with Ustekinumab in Moderate-to-Severe Psoriasis: 24-Week Results from IXORA-S, a Phase III Study99. Comparison of Phenotype, Comorbidities, Therapy and Adverse Events between Psoriatic Patients with and without Psoriatic Arthritis. Biobadaderm Registry100. Depression and Suicidality in Psoriasis: Review of the Literature Including the Cytokine Theory of Depression101. Development of Paradoxical Inflammatory Disorders During Treatment of Psoriasis with TNF Inhibitors: A Review of Published Cases102. Effects of Wannachawee Recipe with Antipsoriatic Activity on Suppressing Inflammatory Cytokine Production in HaCaT Human Keratinocytes103. Effectiveness of Lipid-lowering Statin Therapy in Patients with and without Psoriasis104. Effects of Nanoparticles with Hydrotropic Nicotinamide on Tacrolimus: Permeability through Psoriatic Skin and Antipsoriatic and Antiproliferative Activities105. Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials106. Effectiveness and Safety of Secukinumab in 69 Patients with Moderate to Severe Plaque Psoriasis: A Retrospective Multicenter Study107. Diagnosis and Management of Psoriasis 129108. Early Relapse of Psoriasis after Stopping Brodalumab: A Retrospective Cohort Study in 77 Patients109. Emerging Targeted Therapies for Plaque Psoriasis – Impact of Ixekizumab110. Infections from Seven Clinical Trials of Ixekizumab, an Anti-interleukin-17A Monoclonal Antibody, in Patients with Moderate-to-Severe Psoriasis111. High Rate of Systemic Corticosteroid Prescription among Outpatient Visits for Psoriasis: A Population-based Epidemiological Study Using the Korean National Health Insurance Database112. Hyperuricemia Is an Independent Risk Factor for Psoriatic Arthritis in Psoriatic Patients113. How Is Disease Severity Associated with Quality of Life in Psoriasis Patients? Evidence from a Longitudinal Population-based Study in Sweden114. Influence of TNF-alpha Inhibitors and Fumaric Acid Esters on Male Fertility in Psoriasis Patients115. Interval between Onset of Psoriasis and Psoriatic Arthritis Comparing the UK Clinical Practice Research Datalink with a Hospital-based Cohort116. Increased Prevalence of HCV and Hepatic Decompensation in Adults with Psoriasis: A Population-based Study in the United Kingdom117. Evaluation of Adherence Predictors for the Treatment of Moderate to Severe Psoriasis with Biologics: The Importance of Physician-patient Interaction and Communication118. Exploration of Candidate Biomarkers for Human Psoriasis Based on Gas Chromatography-mass Spectrometry Serum Metabolomics119. Increased Frequencies of Basophils, Type 2 Innate Lymphoid Cells and Th2 Cells in Skin of Patients with Atopic Dermatitis but not Psoriasis120. Initiation, Switching, and Cessation of Psoriasis Treatments among Patients with Moderate to Severe Psoriasis in the United States121. Limited Presence of IL-22 Binding Protein, a Natural IL-22 Inhibitor, Strengthens Psoriatic Skin Inflammation122. Long-term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-year Interim Analysis of the ESPRIT Registry123. Lymphopenia and CD4+/CD8+ Cell Reduction under Fumaric Acid Esters124. Magnetic Resonance Imaging in Psoriatic Arthritis: A Descriptive Study of Indications, Features and Effect on Treatment Change125. Minimal Disease Activity in Patients with Psoriatic Arthritis Treated with Ustekinumab: Results from a 24-week Real-world Study126. Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-Treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis127. Topical Therapies for Psoriasis128. Psoriasis and Comorbid Diseases: Implications for Management129. Translating Psoriasis Guidelines into Practice: Important Gaps Revealed